Imaging SV2A in mood disorders
- Study HIC#:1511016789
- Last Updated:03/26/2024
The goal of the study is to determine whether there are alterations in synaptic vesicle glycoprotein 2A (SV2A), a protein expressed ubiquitously in synaptic vesicles, in depression and anxiety and whether ketamine, an N-Methyl-D-aspartate (NMDA) antagonist, normalizes SV2A density at time of its greatest anti-depressant response. We will conduct an examination of SV2A and associated consequences using neuroreceptor imaging and behavioral techniques.
- Age18 years - 70 years
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Sarah Boster
- Phone Number: 1-203-737-7066
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
The goal of the study is to determine whether there are alterations in synaptic vesicle glycoprotein 2A (SV2A), a protein expressed ubiquitously in synaptic vesicles, in depression and anxiety and whether ketamine, an N-Methyl-D-aspartate (NMDA) antagonist, normalizes SV2A density at time of its greatest anti-depressant response. We will conduct an examination of SV2A and associated consequences using neuroreceptor imaging and behavioral techniques.
Eligibility Criteria
Inclusion Criteria:
Medically healthy individuals, ages 18-70, with a diagnosis of major depressive disorder (MDD), bipolar disorder, or Post-Traumatic Stress Disorder (PTSD). We also accept healthy controls.
